Lara Termini
University of São Paulo
31 Papers
48 Citations
Lara Termini is an academic researcher from University of São Paulo. The author has contributed to research in topics: Cancer & Cervical cancer. The author has an hindex of 14, co-authored 28 publications. Previous affiliations of Lara Termini include Ludwig Institute for Cancer Research.
Chat about Author
Papers
Oxidative stress in female cancers.
TL;DR: The role of OS and the interplay with environmental, host and viral factors related to breast, cervical and ovarian cancers initiation, promotion and progression is described and the role of the natural antioxidant compound curcumin and other compounds for breast, female cancers prevention/treatment is discussed.
Microbiome and Cervical Cancer.
Cristina Paula Castanheira,Mayara Luciana Sallas,Rafaella Almeida Lima Nunes,Noely Paula Cristina Lorenzi,Lara Termini +4 more
TL;DR: The current knowledge concerning changes in vaginal microbiome and cervical disease is summarized and the potential functional interplay between specific bacterial groups and HPV infection outcomes is discussed.
HPV16 Oncoproteins Induce MMPs/RECK-TIMP-2 Imbalance in Primary Keratinocytes: Possible Implications in Cervical Carcinogenesis
Laura Beatriz da Silva Cardeal,Enrique Boccardo,Enrique Boccardo,Lara Termini,Tatiana Rabachini,Maria Antonieta Andreoli,Celso di Loreto,Adhemar Longatto Filho,Luisa L. Villa,Silvya Stuchi Maria-Engler +9 more
TL;DR: The results indicate that HPV oncoproteins promote MMPs/RECK-TIMP-2 imbalance which may be involved in HPV-associated lesions outcome and a decrease in RECK expression levels in precancer and cancer lesions.
Oxidative stress: therapeutic approaches for cervical cancer treatment.
Gabriela Ávila Fernandes Silva,Rafaella Almeida Lima Nunes,Mirian Galliote Morale,Enrique Boccardo,Francisco Aguayo,Lara Termini +5 more
TL;DR: Specific molecules and mechanisms that can act against or together with oxidative stress are discussed, presenting alternatives for cervical cancer prevention and treatment.
43
Diacerein: A potential multi-target therapeutic drug for COVID-19.
Pedro Goncalves de Oliveira,Lara Termini,Edison Luiz Durigon,Ana Paula Lepique,Andrei C. Sposito,Enrique Boccardo +5 more
TL;DR: It is hypothesized that DAR, an anthraquinone derivative drug whose active metabolite is rhein, is a multi-target drug useful for COVID-19 treatment, and may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection.
41